Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study

Purpose. Dry eye disease (DED) can be triggered using preserved ophthalmic formulations or prostaglandin analogs. In this prospective, nonrandomized, open-label pilot study, we evaluated the efficacy of a 0.15% hyaluronic acid (HA) nonpreserved ophthalmic formulation in decreasing DED symptoms in pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Giulia Coco, Danilo Iannetta, Igino Febbraro, Ester Elmo, Gianluca Manni
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2022/1320996
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832552901974687744
author Giulia Coco
Danilo Iannetta
Igino Febbraro
Ester Elmo
Gianluca Manni
author_facet Giulia Coco
Danilo Iannetta
Igino Febbraro
Ester Elmo
Gianluca Manni
author_sort Giulia Coco
collection DOAJ
description Purpose. Dry eye disease (DED) can be triggered using preserved ophthalmic formulations or prostaglandin analogs. In this prospective, nonrandomized, open-label pilot study, we evaluated the efficacy of a 0.15% hyaluronic acid (HA) nonpreserved ophthalmic formulation in decreasing DED symptoms in patients with open-angle glaucoma treated with prostaglandin analogs. Methods. 30 patients with DED receiving chronic treatment with prostaglandin analogs for primary open-angle glaucoma or ocular hypertension were administered ophthalmic formulations 3 times daily for 12 weeks. Foreign body sensation, burning, stinging, dryness, pain, frequency of symptoms, Ocular Surface Disease Index (OSDI), conjunctival hyperaemia, corneal fluorescein staining (CFS), tear film break-up time (TBUT), best-corrected visual acuity, Schirmer test results, and 25-item National Eye Institute Visual Function Questionnaire score between the baseline and 4 and 12 weeks were evaluated. Results. The analysis shows that all primary endpoints improved; in particular, burning sensation and the frequency of symptoms after 4 and 12 weeks of treatment (p<0.001) and dryness and pain after 12 weeks of treatment (p<0.001 and p=0.03, respectively) were reduced significantly. Secondary outcomes confirmed the positive results, with a statistically significant change in the OSDI score and CFS between the baseline and 4 (p=0.02 and p<0.001, respectively) or 12 weeks (both p<0.001) and TBUT after 4 weeks (p=0.01). Conjunctival hyperaemia improved in both eyes in >90% of cases at 12 weeks of treatment. Conclusion. The present study shows that the ophthalmic formulation containing 0.15% HA has a promising beneficial effect on reducing the signs and symptoms of DED in patients treated with prostaglandin analogs.
format Article
id doaj-art-2c0f06e1f5934bd08d3ba9fcf675baeb
institution Kabale University
issn 2090-0058
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Journal of Ophthalmology
spelling doaj-art-2c0f06e1f5934bd08d3ba9fcf675baeb2025-02-03T05:57:26ZengWileyJournal of Ophthalmology2090-00582022-01-01202210.1155/2022/1320996Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot StudyGiulia Coco0Danilo Iannetta1Igino Febbraro2Ester Elmo3Gianluca Manni4Department of Clinical Sciences and Translational MedicineOphthalmology UnitDepartment of Clinical Sciences and Translational MedicineDepartment of Clinical Sciences and Translational MedicineDepartment of Clinical Sciences and Translational MedicinePurpose. Dry eye disease (DED) can be triggered using preserved ophthalmic formulations or prostaglandin analogs. In this prospective, nonrandomized, open-label pilot study, we evaluated the efficacy of a 0.15% hyaluronic acid (HA) nonpreserved ophthalmic formulation in decreasing DED symptoms in patients with open-angle glaucoma treated with prostaglandin analogs. Methods. 30 patients with DED receiving chronic treatment with prostaglandin analogs for primary open-angle glaucoma or ocular hypertension were administered ophthalmic formulations 3 times daily for 12 weeks. Foreign body sensation, burning, stinging, dryness, pain, frequency of symptoms, Ocular Surface Disease Index (OSDI), conjunctival hyperaemia, corneal fluorescein staining (CFS), tear film break-up time (TBUT), best-corrected visual acuity, Schirmer test results, and 25-item National Eye Institute Visual Function Questionnaire score between the baseline and 4 and 12 weeks were evaluated. Results. The analysis shows that all primary endpoints improved; in particular, burning sensation and the frequency of symptoms after 4 and 12 weeks of treatment (p<0.001) and dryness and pain after 12 weeks of treatment (p<0.001 and p=0.03, respectively) were reduced significantly. Secondary outcomes confirmed the positive results, with a statistically significant change in the OSDI score and CFS between the baseline and 4 (p=0.02 and p<0.001, respectively) or 12 weeks (both p<0.001) and TBUT after 4 weeks (p=0.01). Conjunctival hyperaemia improved in both eyes in >90% of cases at 12 weeks of treatment. Conclusion. The present study shows that the ophthalmic formulation containing 0.15% HA has a promising beneficial effect on reducing the signs and symptoms of DED in patients treated with prostaglandin analogs.http://dx.doi.org/10.1155/2022/1320996
spellingShingle Giulia Coco
Danilo Iannetta
Igino Febbraro
Ester Elmo
Gianluca Manni
Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study
Journal of Ophthalmology
title Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study
title_full Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study
title_fullStr Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study
title_full_unstemmed Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study
title_short Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study
title_sort efficacy of nonpreserved sodium hyaluronate artificial tears in dry eye disease patients treated with prostaglandin analogs for primary open angle glaucoma a prospective nonrandomized open label pilot study
url http://dx.doi.org/10.1155/2022/1320996
work_keys_str_mv AT giuliacoco efficacyofnonpreservedsodiumhyaluronateartificialtearsindryeyediseasepatientstreatedwithprostaglandinanalogsforprimaryopenangleglaucomaaprospectivenonrandomizedopenlabelpilotstudy
AT daniloiannetta efficacyofnonpreservedsodiumhyaluronateartificialtearsindryeyediseasepatientstreatedwithprostaglandinanalogsforprimaryopenangleglaucomaaprospectivenonrandomizedopenlabelpilotstudy
AT iginofebbraro efficacyofnonpreservedsodiumhyaluronateartificialtearsindryeyediseasepatientstreatedwithprostaglandinanalogsforprimaryopenangleglaucomaaprospectivenonrandomizedopenlabelpilotstudy
AT esterelmo efficacyofnonpreservedsodiumhyaluronateartificialtearsindryeyediseasepatientstreatedwithprostaglandinanalogsforprimaryopenangleglaucomaaprospectivenonrandomizedopenlabelpilotstudy
AT gianlucamanni efficacyofnonpreservedsodiumhyaluronateartificialtearsindryeyediseasepatientstreatedwithprostaglandinanalogsforprimaryopenangleglaucomaaprospectivenonrandomizedopenlabelpilotstudy